BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...
Independent Study Shows Significant Decline in Cardiac Device Infections with TYRX® Antibacterial Envelope
News | 05. 10. 2013
TYRX
New Data in High Risk Patients Presented at Heart Rhythm Society
Shows a 70% Reduction in CIED Infections
Denver, CO (May 10, 2013): Use of TYRX, Inc.’s AIGISRx® Antibacterial Envelope significantly reduced device infection rates in patients at high risk for device infection who received cardiovascular implantable electronic device (CIED) implants, according to a study presented today at Heart Rhythm 2013, the Heart Rhythm Society’s 34th Annual Scientific Sessions.
